Michelle Gilson analyst

Currently out of the existing stock ratings of Michelle Gilson, 54 are a BUY (96.43%), 2 are a HOLD (3.57%).

Michelle Gilson

Work Performance Price Targets & Ratings Chart

Analyst Michelle Gilson works with a stock forecast success ratio of 43.86% fulfilled within 135.82 days on average. Previously, Michelle Gilson worked at CANACCORD.

Michelle Gilson’s has documented 104 price targets and ratings displayed on 12 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on VIR, Vir Biotechnology at 21-Jul-2023.

Wall Street Analyst Michelle Gilson

Analyst best performing recommendations are on SRPT (SAREPTA THERAPEUTICS).
The best stock recommendation documented was for SRPT (SAREPTA THERAPEUTICS) at 9/14/2016. The price target of $60 was fulfilled within 8 days with a profit of $27.55 (84.9%) receiving and performance score of 106.12.

Average potential price target upside

ASND Ascendis Pharma AS BMRN Biomarin Pharmaceutical CCXI ChemoCentryx FIXX Homology Medicines SGTX Sigilon Therapeutics  SRPT Sarepta Therapeutics STOK Stoke Therapeutics TVTX Travere Therapeutics RTRX Travere Therapeutics AMYT Amryt Pharma Holdings Ltd RZLT Rezolute VIR Vir Biotechnology

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

167

$18.12 (12.17%)

146

11 days ago

14/15 (93.33%)

$15.02 (9.88%)

120

Buy

173

$24.12 (16.20%)

173

11 days ago

4/8 (50%)

$21.02 (13.83%)

218

Buy

182

$33.12 (22.25%)

163

2 months 5 days ago

2/9 (22.22%)

$42.75 (30.70%)

445

Buy

225

$76.12 (51.13%)

192

2 months 5 days ago

1/9 (11.11%)

$85.75 (61.58%)

470

Buy

156

$7.12 (4.78%)

113

2 months 22 days ago

8/9 (88.89%)

$21.84 (16.28%)

150

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What Year was the first public recommendation made by Michelle Gilson?

On 2016

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?